BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vajro P, Lenta S, Pignata C, Salerno M, D’Aniello R, De Micco I, Paolella G, Parenti G. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Ital J Pediatr. 2012;38:55. [PMID: 23075296 DOI: 10.1186/1824-7288-38-55] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. J Pediatr Gastroenterol Nutr 2017;64:413-7. [PMID: 28230607 DOI: 10.1097/MPG.0000000000001422] [Cited by in Crossref: 89] [Cited by in F6Publishing: 44] [Article Influence: 22.3] [Reference Citation Analysis]
2 Tovo CV, Fernandes SA, Buss C, de Mattos AA. Sarcopenia and non-alcoholic fatty liver disease: Is there a relationship? A systematic review. World J Hepatol 2017; 9(6): 326-332 [PMID: 28293382 DOI: 10.4254/wjh.v9.i6.326] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
3 Liyanagedera S, Williams RP, Veraldi S, Nobili V, Mann JP. The pharmacological management of NAFLD in children and adolescents. Expert Rev Clin Pharmacol 2017;10:1225-37. [PMID: 28803504 DOI: 10.1080/17512433.2017.1365599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
4 Wan S, Zhang L, Quan Y, Wei K. Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy. R Soc Open Sci 2018;5:181457. [PMID: 30564426 DOI: 10.1098/rsos.181457] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
5 Buss C, Valle-tovo C, Miozzo S, Mattos AAD. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients. Annals of Hepatology 2014;13:482-8. [DOI: 10.1016/s1665-2681(19)31246-3] [Cited by in Crossref: 27] [Article Influence: 3.4] [Reference Citation Analysis]
6 Troisi J, Belmonte F, Bisogno A, Pierri L, Colucci A, Scala G, Cavallo P, Mandato C, Di Nuzzi A, Di Michele L, Delli Bovi AP, Guercio Nuzio S, Vajro P. Metabolomic Salivary Signature of Pediatric Obesity Related Liver Disease and Metabolic Syndrome. Nutrients 2019;11:E274. [PMID: 30691143 DOI: 10.3390/nu11020274] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
7 Tzifi F, Fretzayas A, Chrousos G, Kanaka-Gantenbein C. Non-alcoholic fatty liver infiltration in children: an underdiagnosed evolving disease. Hormones (Athens) 2019;18:255-65. [PMID: 31140156 DOI: 10.1007/s42000-019-00107-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Troisi J, Pierri L, Landolfi A, Marciano F, Bisogno A, Belmonte F, Palladino C, Guercio Nuzio S, Campiglia P, Vajro P. Urinary Metabolomics in Pediatric Obesity and NAFLD Identifies Metabolic Pathways/Metabolites Related to Dietary Habits and Gut-Liver Axis Perturbations. Nutrients 2017;9:E485. [PMID: 28492501 DOI: 10.3390/nu9050485] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
9 Vajro P, Mandato C, D'Aniello R. More on current evidences on probiotics as a novel treatment for non-alcoholic Fatty liver disease. Hepat Mon 2013;13:e13780. [PMID: 24130602 DOI: 10.5812/hepatmon.13780] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Chen Y, Xu C, Yan T, Yu C, Li Y. ω-3 Fatty acids reverse lipotoxity through induction of autophagy in nonalcoholic fatty liver disease. Nutrition 2015;31:1423-1429.e2. [DOI: 10.1016/j.nut.2015.05.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
11 Stachowska E, Portincasa P, Jamioł-Milc D, Maciejewska-Markiewicz D, Skonieczna-Żydecka K. The Relationship between Prebiotic Supplementation and Anthropometric and Biochemical Parameters in Patients with NAFLD-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2020;12:E3460. [PMID: 33187278 DOI: 10.3390/nu12113460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Rahimlou M, Ahmadnia H, Hekmatdoost A. Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. World J Hepatol 2015; 7(25): 2597-2602 [PMID: 26557952 DOI: 10.4254/wjh.v7.i25.2597] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
13 Holterman A, Gurria J, Tanpure S, Disomma N. Nonalcoholic fatty liver disease and bariatric surgery in adolescents. Seminars in Pediatric Surgery 2014;23:49-57. [DOI: 10.1053/j.sempedsurg.2013.10.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
14 Spahis S, Alvarez F, Dubois J, Ahmed N, Peretti N, Levy E. Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: Effect of n-3 PUFA supplementation. Prostaglandins Leukot Essent Fatty Acids. 2015;99:25-34. [PMID: 26066299 DOI: 10.1016/j.plefa.2015.04.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
15 Azizi Kutenaee M, Amirjani S, Asemi Z, Taghavi SA, Allan H, Kamalnadian SN, Khashavi Z, Bazarganipour F. The impact of depression, self-esteem, and body image on sleep quality in patients with PCOS: a cross-sectional study. Sleep Breath 2020;24:1027-34. [PMID: 31630370 DOI: 10.1007/s11325-019-01946-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
16 Delli Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, Vajro P. Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. Front Med (Lausanne) 2021;8:595371. [PMID: 33718398 DOI: 10.3389/fmed.2021.595371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
17 AlKhater SA. Paediatric non-alcoholic fatty liver disease: an overview. Obes Rev 2015;16:393-405. [PMID: 25753407 DOI: 10.1111/obr.12271] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
18 Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res. 2013;47:869-880. [PMID: 24004441 DOI: 10.3109/10715762.2013.837577] [Cited by in Crossref: 158] [Cited by in F6Publishing: 146] [Article Influence: 17.6] [Reference Citation Analysis]
19 D'Aniello R, Troisi J, D'Amico O, Sangermano M, Massa G, Moccaldo A, Pierri L, Poeta M, Vajro P. Emerging pathomechanisms involved in obesity. J Pediatr Gastroenterol Nutr 2015;60:113-9. [PMID: 25199037 DOI: 10.1097/MPG.0000000000000559] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
20 Mitchel EB, Lavine JE. Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1155-1170. [PMID: 25267322 DOI: 10.1111/apt.12972] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
21 Iraji H, Minasian V, Kelishadi R. Changes in Liver Enzymes and Metabolic Profile in Adolescents with Fatty Liver following Exercise Interventions. Pediatr Gastroenterol Hepatol Nutr 2021;24:54-64. [PMID: 33505894 DOI: 10.5223/pghn.2021.24.1.54] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(42): 15518-15531 [PMID: 25400436 DOI: 10.3748/wjg.v20.i42.15518] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 85] [Article Influence: 11.0] [Reference Citation Analysis]
23 Yao H, Qiao YJ, Zhao YL, Tao XF, Xu LN, Yin LH, Qi Y, Peng JY. Herbal medicines and nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22(30): 6890-6905 [PMID: 27570425 DOI: 10.3748/wjg.v22.i30.6890] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 58] [Article Influence: 11.0] [Reference Citation Analysis]
24 Vajro P, Paolella G, Poeta M, Pizza C, Sangermano M, Massa G. Pediatric non alcoholic fatty liver disease: more on novel treatment targets. BMC Pediatr. 2013;13:109. [PMID: 23870449 DOI: 10.1186/1471-2431-13-109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
25 Machado FHF, Castro Filho HF, Babadopulos RFAL, Rocha HAL, Rocha JLC, Moraes Filho MO. Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass1. Acta Cir Bras 2019;34:e20190010000009. [PMID: 30785510 DOI: 10.1590/s0102-865020190010000009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]